US 9856233
Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins
granted A61PA61P35/00
Quick answer
US patent 9856233 (Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins) held by The Board of Regents of the University of Texas System expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61P, A61P35/00